• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放化疗后手术时机对食管癌患者的肿瘤学结局有影响。

Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer.

作者信息

Shang Qi-Xin, Yang Yu-Shang, Gu Yi-Min, Zeng Xiao-Xi, Zhang Han-Lu, Hu Wei-Peng, Wang Wen-Ping, Chen Long-Qi, Yuan Yong

机构信息

Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.

West China Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.

出版信息

World J Gastrointest Oncol. 2020 Jun 15;12(6):687-698. doi: 10.4251/wjgo.v12.i6.687.

DOI:10.4251/wjgo.v12.i6.687
PMID:32699583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7340997/
Abstract

BACKGROUND

The optimal time interval between neoadjuvant chemoradiotherapy (nCRT) and esophagectomy in esophageal cancer has not been defined.

AIM

To evaluate whether a prolonged time interval between the end of nCRT and surgery has an effect on survival outcome in esophageal cancer patients.

METHODS

We searched PubMed, Embase, Web of Science, the Cochrane Library, Wanfang and China National Knowledge Infrastructure databases for relevant articles published before November 16, 2019, to identify potential studies that evaluated the prognostic role of different time intervals between nCRT and surgery in esophageal cancer. The hazard ratios and 95% confidence intervals (95%CI) were merged to estimate the correlation between the time intervals and survival outcomes in esophageal cancer, esophageal squamous cell carcinoma and adenocarcinoma using fixed- and random-effect models.

RESULTS

This meta-analysis included 12621 patients from 16 studies. The results demonstrated that esophageal cancer patients with a prolonged time interval between the end of nCRT and surgery had significantly worse overall survival (OS) [hazard ratio (HR): 1.107, 95%CI: 1.014-1.208, = 0.023] than those with a shorter time interval. Subgroup analysis showed that poor OS with a prolonged interval was observed based on both the sample size and HRs. There was also significant association between a prolonged time interval and decreased OS in Asian, but not Caucasian patients. In addition, a longer wait time indicated worse OS (HR: 1.385, 95%CI: 1.186-1.616, < 0.001) in patients with adenocarcinoma.

CONCLUSION

A prolonged time interval from the completion of nCRT to surgery is associated with a significant decrease in OS. Thus, esophagectomy should be performed within 7-8 wk after nCRT.

摘要

背景

食管癌新辅助放化疗(nCRT)与食管切除术之间的最佳时间间隔尚未明确。

目的

评估nCRT结束至手术之间延长的时间间隔是否对食管癌患者的生存结局有影响。

方法

我们检索了PubMed、Embase、Web of Science、Cochrane图书馆、万方和中国知网数据库,以查找2019年11月16日前发表的相关文章,以确定评估nCRT与手术之间不同时间间隔对食管癌预后作用的潜在研究。使用固定效应和随机效应模型合并风险比和95%置信区间(95%CI),以估计时间间隔与食管癌、食管鳞状细胞癌和腺癌生存结局之间的相关性。

结果

该荟萃分析纳入了来自16项研究的12621例患者。结果表明,nCRT结束至手术之间时间间隔延长的食管癌患者的总生存期(OS)明显差于时间间隔较短的患者[风险比(HR):1.107,95%CI:1.014 - 1.208,P = 0.023]。亚组分析显示,基于样本量和HRs,均观察到间隔延长导致OS较差。在亚洲患者而非白种人中,时间间隔延长与OS降低之间也存在显著关联。此外,腺癌患者等待时间越长,OS越差(HR:1.385,95%CI:1.186 - 1.616,P < 0.001)。

结论

从完成nCRT到手术的时间间隔延长与OS显著降低相关。因此,应在nCRT后7 - 8周内进行食管切除术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/043c24aea4e4/WJGO-12-687-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/d1c8074065fd/WJGO-12-687-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/219ea6485ee8/WJGO-12-687-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/816699b22ef0/WJGO-12-687-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/f0beb715ebf6/WJGO-12-687-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/043c24aea4e4/WJGO-12-687-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/d1c8074065fd/WJGO-12-687-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/219ea6485ee8/WJGO-12-687-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/816699b22ef0/WJGO-12-687-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/f0beb715ebf6/WJGO-12-687-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db5/7340997/043c24aea4e4/WJGO-12-687-g005.jpg

相似文献

1
Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer.新辅助放化疗后手术时机对食管癌患者的肿瘤学结局有影响。
World J Gastrointest Oncol. 2020 Jun 15;12(6):687-698. doi: 10.4251/wjgo.v12.i6.687.
2
Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.增加食管癌新辅助放化疗与手术之间的间隔时间:已发表研究的荟萃分析
Dis Esophagus. 2016 Nov;29(8):1107-1114. doi: 10.1111/dote.12432. Epub 2015 Nov 6.
3
Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.新辅助放化疗后行食管切除术的时机是否影响疗效?一项荟萃分析。
Int J Surg. 2018 Nov;59:11-18. doi: 10.1016/j.ijsu.2018.09.013. Epub 2018 Sep 24.
4
Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.新辅助放化疗与新辅助化疗治疗局部晚期食管癌的疗效和安全性:一项更新的荟萃分析。
Medicine (Baltimore). 2024 Jan 19;103(3):e36785. doi: 10.1097/MD.0000000000036785.
5
Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis.新辅助放化疗与食管癌切除术之间的间隔时间延长对食管癌预后无益处:一项系统评价和荟萃分析。
Dis Esophagus. 2018 Jan 1;31(1):1-9. doi: 10.1093/dote/dox116.
6
Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).新辅助化疗或放化疗与可切除食管癌患者疗效及安全性相关性的临床证据(NewEC研究)
EClinicalMedicine. 2020 Jun 27;24:100422. doi: 10.1016/j.eclinm.2020.100422. eCollection 2020 Jul.
7
Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis.局部晚期食管癌患者新辅助放化疗与新辅助化疗疗效的比较:一项网状Meta分析。
EClinicalMedicine. 2021 Nov 6;42:101183. doi: 10.1016/j.eclinm.2021.101183. eCollection 2021 Dec.
8
Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.手术方式对新辅助放化疗或未行新辅助放化疗的食管腺癌患者长期生存的影响。
Ann Surg. 2018 May;267(5):892-897. doi: 10.1097/SLA.0000000000002240.
9
Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis.新辅助放化疗与新辅助化疗治疗食管鳞癌的生存和并发症:Meta 分析。
PLoS One. 2022 Aug 5;17(8):e0271242. doi: 10.1371/journal.pone.0271242. eCollection 2022.
10
Comparison of clinical outcomes of conservative treatment and surgery for esophageal cancer patients who achieve a clinical complete response following neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.新辅助放化疗后达到临床完全缓解的食管癌患者保守治疗与手术治疗的临床结局比较:一项系统评价和荟萃分析
Ann Transl Med. 2022 Dec;10(24):1378. doi: 10.21037/atm-22-6186.

引用本文的文献

1
Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?新辅助卡瑞利珠单抗联合化疗至手术的时间间隔是否影响局部晚期食管鳞癌的疗效?
J Cancer Res Clin Oncol. 2024 Mar 27;150(3):161. doi: 10.1007/s00432-024-05696-4.
2
A machine learning approach using F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors.基于 F-FDG PET 和增强 CT 扫描的放射组学与临床模型相结合的机器学习方法,预测新辅助放化疗和抗 PD-1 抑制剂治疗后 ESCC 患者的病理完全缓解。
Front Immunol. 2024 Jan 30;15:1351750. doi: 10.3389/fimmu.2024.1351750. eCollection 2024.
3

本文引用的文献

1
Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.新辅助放化疗与手术时间间隔与食管和胃食管交界处癌完全组织学肿瘤反应的关系:一项全国性队列研究。
Dis Esophagus. 2020 May 15;33(5). doi: 10.1093/dote/doz078.
2
Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.新辅助放化疗后行食管切除术的时机是否影响疗效?一项荟萃分析。
Int J Surg. 2018 Nov;59:11-18. doi: 10.1016/j.ijsu.2018.09.013. Epub 2018 Sep 24.
3
Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus.
Early versus delayed surgery following neoadjuvant chemoradiation for esophageal cancer: a systematic review and meta-analysis.新辅助放化疗后食管癌的早期与延迟手术:系统评价和荟萃分析。
Esophagus. 2023 Jul;20(3):390-401. doi: 10.1007/s10388-023-00989-y. Epub 2023 Feb 17.
新辅助放化疗与手术间隔时间对胸段食管癌鳞状细胞癌患者发病率和生存率的影响
Anticancer Res. 2018 Sep;38(9):5239-5245. doi: 10.21873/anticanres.12848.
4
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.新辅助放化疗联合手术对比单纯手术治疗局部进展期食管鳞癌(NEOCRTEC5010):一项 III 期、多中心、随机、开放标签临床试验。
J Clin Oncol. 2018 Sep 20;36(27):2796-2803. doi: 10.1200/JCO.2018.79.1483. Epub 2018 Aug 8.
5
Timing of esophagectomy after neoadjuvant chemoradiation treatment in squamous cell carcinoma.新辅助放化疗后行食管切除术治疗鳞状细胞癌的时机。
Surgery. 2018 Sep;164(3):455-459. doi: 10.1016/j.surg.2018.04.026. Epub 2018 Jun 11.
6
Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer.对于食管癌,新辅助放化疗后完全病理缓解与食管切除术的时机无关。
J Gastrointest Oncol. 2018 Feb;9(1):73-79. doi: 10.21037/jgo.2017.09.11.
7
Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.新辅助放化疗与食管或食管胃交界癌手术的时间间隔:一项全国性研究。
Eur J Cancer. 2018 Mar;91:76-85. doi: 10.1016/j.ejca.2017.12.009. Epub 2018 Jan 30.
8
Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis.新辅助放化疗与食管癌切除术之间的间隔时间延长对食管癌预后无益处:一项系统评价和荟萃分析。
Dis Esophagus. 2018 Jan 1;31(1):1-9. doi: 10.1093/dote/dox116.
9
Appropriate timing for surgery after neoadjuvant chemoradiation for esophageal cancer.食管癌新辅助放化疗后手术的合适时机。
Dis Esophagus. 2017 Sep 1;30(9):1-8. doi: 10.1093/dote/dox062.
10
Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?新辅助放化疗后行食管腺癌切除术:最佳时机是什么?
Eur J Cardiothorac Surg. 2017 Sep 1;52(3):543-551. doi: 10.1093/ejcts/ezx132.